Contineum Therapeutics Class Stock Market Outlook
| CTNM Stock | 14.44 0.44 2.96% |
About 54% of Contineum Therapeutics' investor base is interested to short. The analysis of overall sentiment of trading Contineum Therapeutics Class stock suggests that many investors are impartial at this time. Contineum Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Contineum Therapeutics Class. Many technical investors use Contineum Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Comfort Level 46
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Contineum Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Contineum Therapeutics Class.
News SentimentBullish | Hype SentimentBearish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Contineum Therapeutics Class is 'Strong Sell'. The recommendation algorithm takes into account all of Contineum Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Contineum | Build AI portfolio with Contineum Stock |
Execute Contineum Therapeutics Advice
The Contineum recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Contineum Therapeutics Class. Macroaxis does not own or have any residual interests in Contineum Therapeutics Class or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Contineum Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Fair | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Contineum Therapeutics Class has a Mean Deviation of 3.4, Semi Deviation of 4.12, Standard Deviation of 4.85, Variance of 23.52, Downside Variance of 21.23 and Semi Variance of 16.94Our trade advice tool can cross-verify current analyst consensus on Contineum Therapeutics and to analyze the company potential to grow in the current economic cycle. To make sure Contineum Therapeutics is not overpriced, please confirm all Contineum Therapeutics fundamentals, including its net income, as well as the relationship between the earnings per share and retained earnings . Given that Contineum Therapeutics has a shares owned by institutions of 62.00 %, we suggest you to validate Contineum Therapeutics Class market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Contineum Therapeutics Trading Alerts and Improvement Suggestions
| Contineum Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (42.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Contineum Therapeutics generates negative cash flow from operations | |
| Contineum Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 62.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 400 shares by Daniel Lorrain of Contineum Therapeutics at 1.01 subject to Rule 16b-3 |
Contineum Therapeutics Returns Distribution Density
The distribution of Contineum Therapeutics' historical returns is an attempt to chart the uncertainty of Contineum Therapeutics' future price movements. The chart of the probability distribution of Contineum Therapeutics daily returns describes the distribution of returns around its average expected value. We use Contineum Therapeutics Class price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Contineum Therapeutics returns is essential to provide solid investment analysis for Contineum Therapeutics.
| Mean Return | 0.55 | Value At Risk | -5.55 | Potential Upside | 7.99 | Standard Deviation | 4.85 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Contineum Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Contineum Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Contineum Therapeutics or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Contineum Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Contineum stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.56 | |
β | Beta against Dow Jones | -0.31 | |
σ | Overall volatility | 4.93 | |
Ir | Information ratio | 0.1 |
Contineum Therapeutics Volatility Alert
Contineum Therapeutics Class exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Contineum Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Contineum Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Contineum Therapeutics Fundamentals Vs Peers
Comparing Contineum Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Contineum Therapeutics' direct or indirect competition across all of the common fundamentals between Contineum Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Contineum Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Contineum Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Contineum Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Contineum Therapeutics to competition |
| Fundamentals | Contineum Therapeutics | Peer Average |
| Return On Equity | -0.3 | -0.31 |
| Return On Asset | -0.21 | -0.14 |
| Current Valuation | 350.57 M | 16.62 B |
| Shares Outstanding | 30.45 M | 571.82 M |
| Shares Owned By Insiders | 1.14 % | 10.09 % |
| Shares Owned By Institutions | 62.00 % | 39.21 % |
| Number Of Shares Shorted | 2.6 M | 4.71 M |
| Price To Book | 2.92 X | 9.51 X |
| Price To Sales | 11.15 X | 11.42 X |
| EBITDA | (42 M) | 3.9 B |
| Net Income | (42.26 M) | 570.98 M |
| Total Debt | 6.26 M | 5.32 B |
| Book Value Per Share | 6.18 X | 1.93 K |
| Cash Flow From Operations | (32.84 M) | 971.22 M |
| Short Ratio | 9.87 X | 4.00 X |
| Earnings Per Share | (2.25) X | 3.12 X |
| Target Price | 20.33 | |
| Number Of Employees | 41 | 18.84 K |
| Market Capitalization | 527.49 M | 19.03 B |
| Total Asset | 212.85 M | 29.47 B |
| Retained Earnings | (117.4 M) | 9.33 B |
| Working Capital | 196.41 M | 1.48 B |
| Net Asset | 212.85 M |
Note: Disposition of 400 shares by Daniel Lorrain of Contineum Therapeutics at 1.01 subject to Rule 16b-3 [view details]
Contineum Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Contineum . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Contineum Therapeutics Buy or Sell Advice
When is the right time to buy or sell Contineum Therapeutics Class? Buying financial instruments such as Contineum Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Contineum Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Realty Funds Thematic Idea Now
Realty Funds
Funds or Etfs investing in real estate backed instruments or issues backed by different types of commercial properties. The Realty Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Realty Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Contineum Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Pharmaceuticals sector continue expanding? Could Contineum diversify its offerings? Factors like these will boost the valuation of Contineum Therapeutics. Projected growth potential of Contineum fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Contineum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Contineum Therapeutics requires distinguishing between market price and book value, where the latter reflects Contineum's accounting equity. The concept of intrinsic value - what Contineum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Contineum Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Contineum Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Contineum Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Contineum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.